Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, to close at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. alleging securities fraud that affected investors between March 13, 2023, and March 11, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The complaint suggests that Zynex may face adverse consequences such as removal from insurer networks and federal penalties due to these practices [2]. - Defendants' positive statements regarding Zynex's business and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the specified timeframe have until May 19, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

PHILADELPHIA, April 10, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of ...

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements and inflating revenue through improper shipping practices during the class period from March 13, 2023, to March 11, 2025 [2]. Group 1: Allegations and Legal Context - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [2]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased shares of Zynex during the specified class period are encouraged to register for the class action lawsuit by May 19, 2025 [3]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [3]. - There is no cost or obligation for shareholders to participate in this case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [4].

PHILADELPHIA, April 9, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired ZYNEX securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the c ...

Core Viewpoint - A class action securities lawsuit has been filed against Zynex, Inc. alleging securities fraud that affected investors between March 13, 2023, and March 11, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue [2]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including the U.S. military health insurance program, Tricare [2]. - The lawsuit suggests that Zynex may face adverse consequences such as removal from insurer networks and penalties from the federal government due to these practices [2]. - Defendants' positive statements regarding Zynex's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Zynex, Inc. during the relevant time frame have until May 19, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Zynex, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business practices, particularly concerning inflated revenue and improper claims submissions [1][2]. Allegations - The complaint alleges that Zynex shipped products, including electrodes, in excess of need, leading to inflated revenue figures [1]. - The company's practice of filing false claims has drawn scrutiny from insurers, including the U.S. military health insurance program, Tricare [1]. - As a result of these practices, Zynex is likely to face adverse consequences, including potential removal from insurer networks and penalties from the federal government [1]. - The positive statements made by the defendants about Zynex's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - The class period for the lawsuit is from March 13, 2023, to March 11, 2025 [1]. - Shareholders who purchased shares during this period are encouraged to register for the class action by May 19, 2025 [2]. - Participants will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by May 19, 2025 [2][4]. Group 1: Allegations Against Zynex - The complaint alleges that Zynex and its executives made false or misleading statements and failed to disclose critical information, including shipping excess products, inflating revenue, and facing scrutiny from insurers like Tricare [4]. - A report published by medical journal STAT accused Zynex of an "oversupplying scheme," leading to insurers removing the company from their networks [5]. - Following the report, Zynex's stock price dropped by $0.50 per share, or 5%, closing at $9.35 on June 4, 2024, amid heavy trading volume [5]. Group 2: Financial Performance and Market Reaction - On March 11, 2025, Zynex reported a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers and a temporary suspension of payments from Tricare [6]. - The announcement led to a drastic decline in Zynex's stock price, which fell by $3.59 per share, or 51.3%, closing at $3.41 on March 12, 2025, also on unusually heavy trading volume [7].

Core Message - Zynex Inc is focused on providing noninvasive, non-addictive at-home pain management solutions through its flagship device, NexWave, addressing the opioid crisis by offering alternative pain management options for healthcare providers and patients [1][5]. Company Overview - Zynex Medical's mission is to combat the opioid crisis by offering alternatives for pain management, which aligns with the company's culture and growth strategy [4][9]. - The company has nearly 300 sales representatives across the U.S. dedicated to educating healthcare providers about non-opioid pain management options [5]. Product Details - NexWave is a 3-in-1 device that incorporates TENS (Transcutaneous Electrical Nerve Stimulation), IFC (Interferential Current), and NMES (Neuromuscular Electrical Stimulation), making it versatile for rehabilitation and pain management [6]. - The device is designed to be user-friendly and effective, particularly for muscle re-education and post-operative care [6]. Growth Strategy - The company has experienced significant growth and aims to expand its reach by educating more healthcare providers and increasing brand awareness [7]. - Current growth efforts are primarily focused on the U.S. market, which presents substantial opportunities for outreach and education [8]. Demographic Alignment - With an aging population increasingly seeking non-surgical pain management solutions, Zynex's offerings are well-positioned to meet this demand, particularly among elderly patients who are looking for non-opioid alternatives [10].